That is a problem for several reasons: GLP-1 medications carry boxed warnings about thyroid C-cell tumors in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2
While lixisenatide and exenatide demonstrate relatively rapid and direct action within central circuits, liraglutide and semaglutide may exert their effects more slowly or indirectly, potentially relying on longer systemic exposure, slow diffusion, or action through peripheralcentral pathways
Document everything get the representative's name, reference number, and the specific formulary tier
A pragmatic alternative is to prepare smaller vials from your reconstituted stock and freeze them as single-use aliquots at 20C, minimizing repeated freeze-thaw exposure to your main vial
The biggest risks are quality, dosing, and sourcing: potency, sterility, salt/form differences, and unclear pharmacy oversight matter more than the headline price
Its important to mention here that not everyone who has taken a GLP-1 gives it such a glowing report card
%20(1).png)
